Swiss ministers met with senior executives from Roche and Novartis to discuss the potential impact of U.S. import tariffs on pharmaceuticals. While pharmaceuticals currently avoid these tariffs, an ...

Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the ...

The Swiss government met with executives of Roche Holding AG and Novartis AG to discuss the pharmaceutical industry’s situation in light of US tariffs.

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Novartis Pharmaceuticals filed a lawsuit against the State of Rhode Island seeking to block the enforcement of a new state ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Schuyler County is to receive a settlement from a New Jersey pharmaceutical company and its affiliates after the county argued it contributed to the ongoing opioid ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...